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ABSTRACT
Introduction: Malignant pleural mesothelioma (MPM)
is an asbestos-related cancer, which is difficult to
diagnose. Thoracoscopy is frequently required but is
not widely available. An accurate, non-invasive
diagnostic biomarker would allow early specialist
referral, limit diagnostic delays and maximise clinical
trial access. Current markers offer insufficient
sensitivity and are not routinely used. The SOMAmer
proteomic classifier and fibulin-3 have recently
demonstrated sensitivity and specificity exceeding 90%
in retrospective studies. DIAPHRAGM (Diagnostic and
Prognostic Biomarkers in the Rational Assessment of
Mesothelioma) is a suitably powered, multicentre,
prospective observational study designed to determine
whether these markers provide clinically useful
diagnostic and prognostic information.
Methods and analysis: Serum and plasma (for
SOMAscan and fibulin-3, respectively) will be collected
at presentation, prior to pleural biopsy/pleurodesis,
from 83 to 120 patients with MPM, at least 480
patients with non-MPM pleural disease and 109
asbestos-exposed controls. Final numbers of MPM/
non-MPM cases will depend on the incidence of MPM
in the study population (estimated at 13–20%).
Identical sampling and storage protocols will be used
in 22 recruiting centres and histological confirmation
sought in all cases. Markers will be measured using
the SOMAscan proteomic assay (SomaLogic) and a
commercially available fibulin-3 ELISA (USCN Life
Science). The SE in the estimated sensitivity and
specificity will be <5% for each marker and their
performance will be compared with serum mesothelin.
Blood levels will be compared with paired pleural fluid
levels and MPM tumour volume (using MRI) in a
nested substudy. The prognostic value of each marker
will be assessed and a large bioresource created.
Ethics and dissemination: The study has been
approved by the West of Scotland Research Ethics
Committee (Ref: 13/WS/0240). A Trial Management
Group meets on a monthly basis. Results will be
published in peer-reviewed journals, presented
at international meetings and disseminated to
patient groups.
Trial registration number: ISRCTN10079972,
Pre-results.
INTRODUCTION
Malignant pleural mesothelioma (MPM) is
an invasive thoracic malignancy, strongly
associated with prior asbestos exposure. The
median survival for patients with MPM is
poor at 9–10 months.1 2 However, the prog-
nosis of individuals is highly variable and
largely determined by histological subtype.2
MPM frequently presents as an emergency
with a large, symptomatic pleural effusion.3
Early specialist referral is frequently required
because pleural fluid aspiration cytology is
unreliable4 and histological confirmation is
recommended in all patients.5 Thoracoscopy
(under local or general anaesthesia)5
enables widespread tissue sampling6 with
Strengths and limitations of this study
▪ Prospective, multicentre study recruiting a repre-
sentative sample of patients in an
intention-to-diagnose population.
▪ Strict sampling, processing and storage methods
used in all patients.
▪ Robust diagnostics and 12 months’ follow-up.
▪ Creation of a large bioresource annotated with
detailed, prospectively collected clinical informa-
tion, for use in future biomarker discovery and
validation studies.
▪ The final number of study participants with
malignant pleural mesothelioma, and therefore
the power available to test the primary objective,
will not be known until recruitment is complete.
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diagnostic yields for malignancy >90%7 but is not avail-
able in all centres. Thoracoscopy also allows pleurodesis
or indwelling pleural catheter placement.
A reliable, non-invasive diagnostic biomarker for MPM
would be a major clinical advance. This would allow clin-
icians to reliably differentiate likely MPM from second-
ary pleural malignancies (eg, lung or breast cancer),
which may present with similar clinical and imaging fea-
tures but require less evolved diagnostic pathways. This
reflects the improved sensitivity of pleural cytology in
these diseases8–10 and the frequent option of alternative
sites for tissue biopsy. A positive MPM biomarker test
could facilitate early referral to a thoracoscopy centre
and avoid unnecessary diagnostic delay (eg, due to
repeated pleural aspirations), minimising the risk of sub-
sequent needle-tract metastases11 12 and maximising
opportunity for clinical trial enrolment. Previous studies
have demonstrated that blood levels of single proteins,
including mesothelin,13 14 megakaryocyte potentiating
factor (MPF)15 and osteopontin,16 are higher in patients
with MPM than in asbestos-exposed controls (AECs) and
patients with secondary pleural malignancies.
Mesothelin, a cell-adhesion glycoprotein that is overex-
pressed in MPM17 18 is the most widely studied and is
associated with an MPM sensitivity of 56–77% at 95%
specificity14 15 19 but much reduced performance in
patients with non-epithelioid MPM. A recent
meta-analysis (of 4491 individuals (1026 with MPM))
reported a sensitivity of only 32% at 95% specificity.
Mesothelin does not, therefore, contribute to current
diagnostic algorithms.20 MPF offers no advantage over
mesothelin,15 while the clinical utility of osteopontin is
limited by stability and reproducibility concerns.16
An ideal MPM biomarker would be measurable in
blood for ease of collection and offer sufficient sensitivity
at high specificity in patients presenting with suspected
MPM. Differentiation between advanced disease patients
and appropriate controls is of limited value. High specifi-
city is mandatory for a low prevalence disease, and
should apply to patients with asbestos exposure and
non-MPM pleural disease. Biomarker results should also
correlate with disease extent and have defined relation-
ships with potential confounders including renal func-
tion21 and the effect of pleural interventions. The latter
is important because the precedent has been established
in prostate22 23 and breast cancer24 that recent sampling,
resection or peritumoural inflammation may affect bio-
marker expression. This is particularly relevant to MPM
where biopsies are frequently large and often combined
with pleurodesis. Several previous biomarker studies,
which validated inconsistently in external populations,
used samples acquired at later time points, often post-
diagnosis (and postpleurodesis) including samples taken
prior to, during or after resection surgery.16 25 26 The aim
of the DIAPHRAGM (Diagnostic and Prognostic
Biomarkers in the Rational Assessment of Mesothelioma)
study is to prospectively evaluate the diagnostic and prog-
nostic performance of the SOMAscan proteomic
classifier27 and fibulin-3,25 which have demonstrated
high sensitivity and specificity in recent retrospective
series. The study has been designed to generate clinically
meaningful results, which can be related to MPM biology
and confounding factors, and applied to patients at first
presentation.
SOMAmer-based proteomic classifier
The SOMAscan assay is a highly multiplexed proteomic
platform that uses SOMAmer (Slow Off-rate Modified
Aptamers) reagents to selectively bind and quantify pro-
teins.28 A 13-protein classifier was developed by
SomaLogic (Boulder, Colorado, USA); using this novel
proteomics-based biomarker detection technique27 in a
retrospective study, over 800 proteins were measured in
the serum of 117 patients with MPM and 142 AECs, col-
lected at surgical MPM centres in the USA between 1996
and 2011. Using a panel of 13 differentially expressed
proteins and a cut-point of 0.5, the classifier was able to
segregate MPM from controls with an area under the
curve (AUC) of 0.99±0.01 in training (60 MPM/60 con-
trols), 0.98±0.04 in blinded verification (19 MPM/20
controls) and 0.95±0.04 in blinded validation sets (38
cases/62 controls).27 The combined sensitivity for the
three cohorts was 93% at 91% specificity. Based on the
published receiver operating characteristic (ROC) curve
for the validation cohort, sensitivity at 95% specificity
appeared to be ∼78%, although the authors did not
report this value. This performance exceeds that of any
previous MPM biomarker, although the classifier’s speci-
ficity appeared lower in patients with non-MPM pleural
effusion (n=32). There was a modest correlation
between classifier score and disease stage, but prognostic
significance was not assessed. The 13 classifier proteins
(9 upregulated, 4 downregulated) have not previously
been associated with MPM. Their functions fall into two
broad groups: regulation of proliferation and inflamma-
tion. Quite apart from their biological relevance to
MPM, the latter is an important potential confounder
because many of the patients involved will have previ-
ously undergone pleurodesis. In addition, several groups
have reported an independent interaction between
prognosis and inflammatory biomarkers in MPM, includ-
ing neutrophil-to-lymphocyte ratio,29–31 monocytosis32
and the modified Glasgow Prognostic Score.31
Therefore, adequate understanding of the diagnostic
and prognostic utility of this assay requires replication in
a prepleurodesis cohort and prospective evaluation of
interactions between inflammatory biomarkers and
SOMAscan scores.
Fibulin-3
Fibulin-3 is a secreted glycoprotein, encoded by the epi-
dermal growth factor-containing fibulin-like extracellular
matrix protein 1 gene.33 Fibulin-3 is overexpressed in
MPM tumours relative to adjacent benign pleura25 and
expressed and secreted by MPM cell lines.26 Pass et al25
retrospectively measured fibulin-3 in the plasma of
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92 patients with MPM, 136 AECs, 93 patients with
non-MPM pleural effusion and 43 healthy controls. A
plasma cut-point of 52 ng/mL provided 97% sensitivity
at 95% specificity and a 95% CI of the AUC of 0.97 to
0.99 in differentiating MPM from all other cases.
However, in a blinded external validation set, sensitivity
was below 40% (at 95% specificity), with an AUC=0.87.
Subsequent studies have revealed mixed results. In a
study of 153 patients (82 with MPM), Creaney et al14
reported a sensitivity of 22% (at 95% specificity) at the
same 52 ng/mL cut-point and an AUC of 0.671 (0.606
to 0.732), which was significantly inferior to mesothelin
measured in the same patients (sensitivity 56% (at 95%
specificity); AUC 0.816 (0.755 to 0.867)) at a 2.5 nM
threshold). In a small Egyptian study using an unspeci-
fied fibulin-3 assay and internally defined cut-points,
Agha et al34 reported 100% sensitivity/78% specificity in
differentiating MPM cases (n=25) from non-malignant
pleural disease (n=9), and 88% sensitivity/82% specifi-
city in differentiating MPM from secondary pleural
malignancies (n=11). No combined sensitivity was
reported. An Italian study found no difference in
fibulin-3 levels but used serum (not plasma), a control
group without pleural disease (asbestosis) and contained
only 14 patients with MPM.35
METHODS AND ANALYSIS
Study design
DIAPHRAGM is a prospective, multicentre observational
study. The study incorporates sampling windows that cor-
respond to the proposed use of a diagnostic biomarker,
that is, at presentation with suspected pleural malig-
nancy (SPM). The overall study design is summarised in
figure 1A, B. The main impact of this design is that bio-
markers will be drawn before a diagnosis is made. In
addition to better replicating the future use of these
markers, this avoids the potential confounding effect of
pleurodesis on biomarker results. The diagnostic per-
formance of the SOMAmer panel and fibulin-3 will be
assessed using cut-points determined in the relevant ori-
ginal studies and compared with mesothelin (using the
MESOMARK ELISA (Fujirebio Diagnostics)). Identical
processing and storage protocols will be used in patients
with SPM and a group of AECs. Potential confounders
including renal function, inflammatory indices and
drugs will be recorded at all visits. The timing of the bio-
marker blood draw in relation to pleural aspiration (pre-
aspiration or postaspiration) will be recorded in order to
assess the effect of this intervention on biomarker
results. An exploratory, cross-sectional MRI substudy will
determine if there is any correlation between blood bio-
marker levels and MPM tumour volume, as has been
established for mesothelin using CT-positron emission
tomography scanning.36
Study objectives and outcome measures
These are presented in table 1.
Setting
At least 600 consecutive patients with SPM will be
recruited from 22 centres (20 in the UK, 1 in Republic
of Ireland). These are a mixture of academic and more
clinically orientated units. This should make the results
of the DIAPHRAGM study generalisable to patients
presenting with SPM to acute hospital services. The
principal criterion used to select centres was that
they had sufficiently evolved pleural diagnostic services
to deliver a reliable diagnosis. Specifically, access to
on-site thoracoscopy (ideally including local anaesthetic
thoracoscopy (LAT)) and a regional mesothelioma
multi-disciplinary team meeting (for diagnostic review
and staging) was required.
Screening and eligibility assessment
Suspected pleural malignancy
Cases will be identified on presentation to a respiratory
outpatient clinic or acute hospital admissions unit. This
will be based on the history, examination and available
investigations. Potentially eligible patients will be pro-
vided with the study patient information sheet (PIS, see
online supplementary appendix 1) and eligibility
assessed based on the following criteria:
Inclusion criteria:
▸ SPM, defined by a unilateral pleural effusion or
pleural mass lesion;
▸ Sufficient fitness for diagnostic sampling (site investi-
gator’s clinical judgement);
▸ Informed written consent.
Exclusion criteria:
▸ Intercostal chest drain in situ, or inserted within the
previous 3 months.
Asbestos-related pleural plaques are not an inclusion
criterion since these are absent in up to 25% of MPM
cases,37 and are also common in asbestos-exposed popu-
lations without MPM.38 Patients with lung nodules or
other visceral mass lesions are not excluded, assuming
the investigator suspects pleural malignancy. This is
because of the high prevalence of lung nodules in the
target population (older patients, commonly smokers)
and the high false-positive rate of CT imaging in this
regard.39
Participants recruited to the SPM arm will generate
cohorts of MPM and non-MPM pleural disease of
various aetiologies, likely including benign asbestos-
related pleural effusion and secondary pleural malignan-
cies. These numbers will be sufficient to address the
primary objective with sufficient statistical power to
inform clinical practice (see later section).
AEC participants
One hundred and nine AECs will be recruited via invita-
tions sent by Clydeside Action on Asbestos (CAA), an
advocacy body based in Glasgow with a database of over
600 clients, or by respiratory clinics at the host centre.
Individuals will be invited to participate by letter (if
identified via CAA) or given the PIS (see online
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Figure 1 Summary of the
design of the DIAPHRAGM study.
(A) Describes the optimal
diagnostic pathway for the
majority of patients who present
with significant pleural effusion
±pleural thickening or a pleural
mass. (B) Describes the optimal
diagnostic pathway for the
minority of patients who present
with an isolated pleural mass, but
no significant fluid component.
The pathway chosen is ultimately
at the discretion of the
investigating physician.
DIAPHRAGM, Diagnostic and
Prognostic Biomarkers in the
Rational Assessment of
Mesothelioma; MPM, malignant
pleural mesothelioma.
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supplementary appendix 2) at clinic. All participants will
be invited to a single research clinic visit assuming the
following eligibility criteria are met.
Inclusion criteria:
▸ Documented history of asbestos exposure and asso-
ciated pleural plaques, asbestosis or diffuse pleural
thickening;
▸ Willing and able to travel to a research clinic inter-
view in Glasgow;
▸ Informed written consent.
Exclusion criteria
▸ Known MPM;
▸ Known or suspected other thoracic malignancy under
investigation;
▸ Known pleural effusion of any cause.
Detailed asbestos exposure histories will be taken from
all participants in the SPM cohort and the AEC cohort.
This will be done using an asbestos exposure question-
naire derived from the Health and Safety Executive
asbestos survey40 (see online supplementary appendix
3). This questionnaire includes recording of the nature
of occupational exposure(s), which can be correlated to
likely fibre exposure. The duration and first year of
exposure is also recorded. Non-occupational sources of
exposure are also recorded (eg, the washing of an occu-
pationally exposed spouse’s work clothes). Only AECs
with documented imaging sequelae of asbestos exposure
(eg, pleural plaques) and an asbestos exposure history
will be included.
Cross-sectional MRI substudy
Fifty patients will be recruited to address the study’s
exploratory objectives (see table 1). Eligibility will be
determined based on the following criteria.
Inclusion criteria:
▸ Pleural histological sampling (by LAT/image-guided
biopsy) indicated to investigate SPM following a non-
diagnostic pleural aspiration;
▸ Recruited in a West of Scotland (WoS) centre.
Exclusion criteria:
▸ Unable to undergo MRI (claustrophobia or known
contraindications such as pacemaker, ferrous metal
implants or foreign body);
▸ Allergy to gadolinium contrast;
▸ Renal impairment (estimated glomerular filtration
rate <30 mL/min);
▸ Pregnancy.
Based on previous audit data from the host centre, we
expect at least 40% (n=20) of patients in the substudy
to have MPM. Eligible participants will be approached
at the clinical visit during which non-diagnostic pleural
aspiration results, and the need for further investigation,
Table 1 Outcome measures used in the DIAPHRAGM study
Research objective Outcome measures
Primary
To determine whether SOMAscan results and/or fibulin-3 levels in
blood at presentation can differentiate MPM from asbestos-exposed
controls and patients with other causes of pleural effusion with a
sufficient degree of sensitivity and specificity to be of routine clinical
value
Serum SOMAscan
Plasma fibulin-3
Final diagnosis reached
Secondary
To determine whether:
1. SOMAscan results and/or fibulin-3 levels at presentation provide
clinically useful prognostic information in patients with MPM
Serum SOMAscan and plasma fibulin-3 at
presentation
Survival (from registration)
2. Early changes in SOMAscan and/or fibulin-3 levels after diagnosis
(at 3 months) are associated with a poorer prognosis in MPM
Serum SOMAscan and plasma fibulin-3 3 months
post-Dx
Survival (from registration)
Exploratory
To determine whether:
1. There is a correlation between SOMAscan and/or fibulin-3 levels in
blood and tumour volume, defined by MRI
Serum SOMAscan
Plasma fibulin-3
MPM tumour volume at MRI, defined using Myrian
Intrasense software
2. There is a correlation between SOMAscan and/or fibulin-3 levels in
blood and tumour angiogenesis (as defined by perfusion-based
MRI biomarkers)
Serum SOMAscan
Plasma fibulin-3
The following MRI biomarkers:
▸ MRI-ECE
▸ Redistribution rate constant (Kep)
▸ Elimination rate constant (Kel)
3. There is a correlation between SOMAscan and/or fibulin-3 levels in
blood and pleural fluid at presentation in patients with MPM
SOMAscan and fibulin-3 at presentation and at
1 month postbiopsy±drainage and pleurodesis
DIAPHRAGM, Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma; MPM, malignant pleural mesothelioma.
Tsim S, et al. BMJ Open 2016;6:e013324. doi:10.1136/bmjopen-2016-013324 5
Open Access
are discussed. Participants will be provided with a
separate PIS (see online supplementary appendix 4)
and will be asked to provide additional informed
written consent.
Consent
All participants will be given sufficient time (as judged
by themselves) to provide written informed consent
after reading the relevant PIS and having the opportun-
ity to ask questions.
Outcome measures
The outcome measures associated with each of the
trial’s objectives are detailed in table 1.
Final diagnosis
A specific cytological or histological pleural diagnosis
will be sought in all patients according to national guide-
lines.20 This will be recorded as the final diagnosis,
which may be based on immediate repeat biopsies felt to
be indicated by the site principal investigator (see figure
1). Any cytologically or histologically confirmed
non-MPM diagnosis (eg, pleural metastases from lung
cancer) will be recorded without the need for any
further updates. However, sites will need to provide
updates for any non-MPM diagnosis that is not cytologi-
cally or histologically confirmed (eg, parapneumonic
effusion). These will be submitted on the 12-month
anniversary of the original diagnosis, or as soon as any
new pleural diagnosis is made. This aims to capture any
false-negative diagnostic tests from the initial presenta-
tion, acknowledging the major diagnostic challenges
posed by pleural malignancies, particularly MPM.
Biomarker sampling and storage
Blood samples (±pleural fluid in WoS centres) will be
drawn and immediate processing performed at each
study centre. Samples can be taken before or after
pleural aspiration. Patients with positive pleural cytology
cannot be recruited (see figure 1A). Duplicate samples
will be collected for all measurements at all visits, ensur-
ing redundancy in case of loss or damage to samples
during transportation to the appropriate central labora-
tory. SOMAmer biomarker levels will be measured in
serum; therefore, 9 mL of venous blood will be collected
first into a vacutainer tube containing serum separator
tube clot activator. Fibulin-3 levels will be measured in
plasma; therefore, 9 mL of venous blood will be col-
lected second into a vacutainer tube containing EDTA.
In centres contributing to the exploratory MRI substudy
(WoS sties only) 20 mL of pleural fluid will be also col-
lected into a plain container if pleural fluid is being
drawn for diagnostic/therapeutic purposes at the same
visit. If not done at this first opportunity, prediagnosis
pleural fluid can also be collected during local anaes-
thetic or general anaesthetic thoracoscopy, prior to any
biopsy or pleurodesis being performed.
Biomarker processing and storage
Serum samples will be allowed to clot for 30 min before
centrifugation. Plasma and pleural fluid samples will be
centrifuged immediately. All samples will be centrifuged
at 2200 g for 15 min at room temperature. For all
samples, the supernatant will be withdrawn by pipette,
aliquoted into cryovials of at least 250 μL volume,
labelled and placed into a −80°C freezer within 2 hours.
Samples will be stored at each recruiting centre until
batched transport to the appropriate study laboratory.
Samples from WoS recruiting centres will be used to
create a bioresource. The bioresource will be stored as a
satellite collection of the NHS Greater Glasgow and
Clyde Biorepository, a Health Improvement Scotland
(HIS)-approved tissue bank. Data will be stored in the
secure Cancer Research UK (CRUK) Clinical Trials Unit
(CTU) database. On study completion, investigators will
be invited to apply for access to data and samples appro-
priate to their research questions. This will allow exter-
nal validation of new markers, including those reported
since the study’s design (such as High Mobility Group
Box-1 (HMGB-1)),41 in an intention-to-diagnose popula-
tion. Access will be granted after peer review of each
proposal by a scientific board comprising members of
the DIAPHRAGM Trial Management Group (TMG) and
senior biorepository staff. An annual update on this
activity will be submitted to the WoS Research Ethics
Committee.
Biomarker analyses
SomaLogic (Boulder, Colorado, USA) will perform all
SOMAscan proteomic analyses.27 This uses SOMAmer
reagents to specifically bind to protein targets in blood.
Relative protein concentrations will be converted to
measurable nucleic acid signals that are quantified by
hybridisation to DNA microarrays.28
Fibulin-3 and mesothelin levels will be measured by
the Translational Pharmacology Unit, Wolfson Wohl
Cancer Research Centre, UK, using ELISA methods vali-
dated according to the Food and Drug Administration
(FDA)-recommended guidelines for bioanalytical
methods.42 Fibulin-3 levels in plasma and pleural fluid
will be measured using the commercially available
ELISA (Cloud-Clone Corp, formerly USCN Life Science,
Houston, Texas, USA) as in the original Pass et al’s25
study. Mesothelin will be measured using the
MESOMARK ELISA (Fujirebio Diagnostics).
MRI
Patients will be scanned at the Queen Elizabeth
University Hospital, Glasgow, on a 3.0T Siemens Verio
MRI Scanner. After localisation of the affected thoracic
cavity, an isotropic three-dimensional T1-weighted
volume will be acquired using volumetric interpolated
breath-hold examination (VIBE) sequences. A stack of
axial slices covering the entire lung and surrounding
pleura will be acquired as a set of short breath holds.
Gadolinium-diethylenetriamine pentaacetic acid contrast
6 Tsim S, et al. BMJ Open 2016;6:e013324. doi:10.1136/bmjopen-2016-013324
Open Access
(Gadovist) will be administered via a peripheral intraven-
ous line as a 15–40 mL bolus (0.05 mmol/kg). VIBE
sequences will be reacquired at copied slice positions to
provide precontrast and postcontrast images. The total
scan time will be around 45 min. Regions of enhancing
pleural tumour will be defined using semiautomated
signal intensity thresholding based on contrast-enhanced
axial slices using Myrian Intrasense software, which has
previously been used to assess tumour volume in
MPM.43 MRI volumetry analyses will be validated using
imaging phantoms.
Survival
Survival will be recorded in days from the date of study
registration to the data of death, from any cause.
Sample size, assumptions and uncertainties
Sample size estimations for each marker were based on
published data at the point of study design and a pro-
jected MPM incidence of 13–20% in the SPM cohort.
The power available to test the hypotheses below is
therefore reported as a range, based on final MPM
numbers lying between 83 (13% incidence) and 120
(20% incidence).
Primary objective
SOMAscan assay
We hypothesise that the MPM sensitivity and specificity
exceed 90%, based on previously reported performance
in combined training, verification and validation sets
(sensitivity 93.2% (88.6% to 97.7%), specificity (90.8%
(86.1% to 95.6%)27). Recruitment of 83–120 patients
with MPM will allow us to distinguish a sensitivity of
>90% from a sensitivity <80% with 80–93% power,
respectively, at the 5% one-sided level of significance.
In total, 83–120 patients with MPM will allow discrimin-
ation between a specificity <80% and a specificity
>90%, with 80–88% power at the 5% one-sided level of
statistical significance. The SE in the estimated sensitiv-
ity and specificity will be <5%, across all possible
outcomes.
Fibulin-3
We hypothesise that the MPM sensitivity will exceed 80%
and that the specificity will exceed 90% (at the 52 ng/
mL cut-off). These figures are based on a reduced level
of performance to the primary results reported by Pass
et al25 (97% sensitivity, 95% specificity), given lower sen-
sitivity in the external validation cohort studied (40% at
95% specificity).
With 83–120 patients with MPM, the study will be able
to distinguish a sensitivity of >80% from a sensitivity
<70% with 65–80% power, respectively, at the 5% one-
sided level of statistical significance. The SE in the esti-
mated sensitivity will be <5%. In order to achieve 90%
power to distinguish a specificity of >90% from a specifi-
city <85% at the 5% one-sided level of statistical signifi-
cance, a random sample of 378 non-MPM samples will
be analysed. The SE in the estimated specificity will be
<2.3%.
The study data will be used to estimate the AUC for
the SOMAscan marker for distinguishing patients with
MPM from non-MPM patients in the SPM cohort.
Assuming 83–120 patients in the MPM group and 83–
120 in the non-MPM group, the AUC can be estimated
with a 95% CI of width 0.120 to 0.168 (assuming a cut-
point exists with a reasonable sensitivity of 80% and a
modest specificity of 40%). If more sensitive/specific
cut-points exist, the width of the 95% CI will be much
reduced. The study data will be used to develop a new
diagnostic signature based on fibulin-3 and SOMAscan
results to distinguish MPM from non-MPM effusions.
Secondary objectives
The study data will be used to determine whether base-
line SOMAscan results and/or fibulin-3 levels, or a
change in levels at 3 months (fibulin-3 only), are inde-
pendent prognostic factors for MPM. A correlation of 0.4
between existing prognostic factors and each marker has
been assumed. For the baseline levels, to detect an
approximate doubling in median overall survival (from 6
to 12 months—a HR of 2) with 80% power and 5% two-
sided level of statistical significance between a good/poor
prognostic group based on dichotomising these markers
requires at least 83 patients with MPM recruited over
3 years with ∼6 months subsequent follow-up to observe
66 deaths. For the 3-month change levels, a HR of 2.38
can be detected (80% power, 5% two-sided level of statis-
tical significance) when 49 deaths are observed in the
estimated 66 out of 83 patients who survive to 3 months.
Exploratory objectives
These will be addressed in the MRI substudy, which will
generate a sample of at least 20 patients with MPM. This
will allow moderately large associations (0.6) between
the exploratory outcome measures (see table 1) to be
detected at 80% power at the 5%, two-sided level of stat-
istical significance. The effect of pleural biopsies±drain-
age/pleurodesis on fibulin-3 levels will be assessed using
all 50 patients recruited. This will allow moderately small
differences (standardised difference of 0.4) to be
detected with 80% power at the 5% two-sided level of
statistical significance.
Statistical analysis plan
Primary analysis
Sensitivity and specificity at prespecified cut-offs will be
estimated using standard approaches for proportions.
The diagnostic performance of each biomarker will be
assessed using ROC curves. All patients with MPM
(n=83–120) will be included and compared with AECs
and a random sample of non-MPM cases. Owing to cost
constraints related to SOMAscan analyses, 83 AECs and
83 non-MPM cases will be randomly selected. All AECs
and 378 non-MPM cases will be used for fibullin-3 ana-
lyses and for comparison with mesothelin. Logistic
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regression will be used to estimate a diagnostic model
using biomarker results and clinical or radiological vari-
ables. Cross-validation will be used to provide robust esti-
mates of AUC and specificity at fixed sensitivity rates of
80%, 90% and 95%.
Secondary analysis
A prognostic model will be developed using Cox propor-
tional hazard techniques. The modelling process will
incorporate biomarker measurements (at presentation
(both markers) and at 3 months (fibulin-3 only) and
other known prognostic features (eg, performance status,
histology).
Exploratory analysis
The association between SOMAscan results/fibulin-3 in
blood and tumour volume/measures of tumour angio-
genesis will be estimated by Pearson or Spearman correl-
ation, depending on the normality of the data. The
same methods will be used to test the association
between fibulin-3 in blood and pleural fluid. Changes in
fibulin-3 levels before and after histological sampling (at
1 month follow-up) will be compared using a paired
t-test or Wilcoxon signed rank-sum test (depending on
the normality of the data). Owing to cost constraints,
exploratory end points involving pleural fluid
SOMAscan results will be analysed at a later date.
Changes to the study protocol since trial opening
The protocol described accurately reflects V.5, of the
protocol, dated 17/6/16. The following changes were
made in previous versions:
▸ V.2, dated 14/2/14:
– Safety reporting reduced following risk assessment
by study sponsor.
– Collection of duplicate blood samples as provision
for loss or damage and for sample retention in
tissue bank.
– Greater flexibility to timing of first blood draw.
▸ V.3, dated 17/10/14:
– Addition of recruitment of controls from respiratory
medicine clinics.
– Addition of exclusion criteria for patients with chest
drains in situ.
– Eligibility for the MRI substudy extended to patients
proceeding to image-guided pleural biopsy.
▸ V.4, dated 27/4/15:
– Update to the exclusion criteria for the AECs to
include known or suspected thoracic malignancy
under investigation.
▸ V.5, dated 17/6/16:
– Power projections adjusted based on interim report-
ing of MPM incidence from recruiting centres.
Definition of end of study
The trial will end 2 years after the last patient with con-
firmed MPM is recruited or whenever all patients with
MPM have died (whichever occurs first).
Monitoring, data management and quality assurance
No on-site monitoring will be undertaken. Two
telephone-monitoring calls will be conducted by a
CRUK Glasgow CTU Monitor to carry out process, com-
pliance and documentation checks. Central monitoring
of trial data will be performed by the trial statistician
and clinical trial coordinator by checking incoming
forms for compliance with the protocol, data consist-
ency, missing data and timing. The CRUK Glasgow CTU
will control data consistency and data quality by entering
trial data onto CTU database. Computerised and
manual consistency checks will be performed and
queries issued in cases of inconsistency or missing infor-
mation. An audit trail of changes to the database will be
maintained.
Safety considerations
Participants in the MRI substudy will be asked at their
1-month follow-up visit about the occurrence of adverse
events related to the administration of MRI contrast
(gadolinium). These will be followed until resolution.
Dissemination
The results of the study will be presented at national
and international scientific meetings and published in
full in a peer-reviewed journal (authorship will be
according to that journal’s guidelines). A lay summary
will be produced and disseminated to interested parties.
Trial management
The trial will be coordinated from the CRUK Glasgow
CTU by the TMG, including the chief investigator,
selected co-investigators, project manager, trial statisti-
cian, clinical trial coordinator and IT staff. The TMG
will oversee the running of the trial and meet monthly.
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